News Website

Nouscom's Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to 'Intercept' Cancer - The Manila Times

Nouscom's Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to 'Intercept' Cancer The Manila Times

Published: Nov. 5, 2024, 2:11 p.m.

Read Full Article

Lisata Therapeutics partners with University of Cincinnati to investigate endometriosis therapy - ICYMI - Proactive Investors USA

Lisata Therapeutics partners with University of Cincinnati to investigate endometriosis therapy - ICYMI Proactive Investors USA

Published: Nov. 2, 2024, noon

Read Full Article

MMR Status Doesn’t Impact Outcomes of Chemo in Endometrial Cancer - Cancer Therapy Advisor

MMR Status Doesn’t Impact Outcomes of Chemo in Endometrial Cancer Cancer Therapy Advisor

Published: Oct. 29, 2024, 2:30 p.m.

Read Full Article

Brachytherapy With Modified Rotte-y Applicator for Inoperable Endometrial Cancer: A Case Report - Cureus

Brachytherapy With Modified Rotte-y Applicator for Inoperable Endometrial Cancer: A Case Report Cureus

Published: Oct. 27, 2024, 7:49 a.m.

Read Full Article

Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation - The Week

Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation The Week

Published: Oct. 25, 2024, 5:28 a.m.

Read Full Article

Hope Medicine touts favourable mid-stage data for endometriosis therapy - FirstWord Pharma

Hope Medicine touts favourable mid-stage data for endometriosis therapy FirstWord Pharma

Published: Oct. 24, 2024, 9:31 p.m.

Read Full Article

Chemotherapy Combinations and the Phase 3 DUO-E Trial - Cancer Network

Chemotherapy Combinations and the Phase 3 DUO-E Trial Cancer Network

Published: Oct. 24, 2024, 6:32 p.m.

Read Full Article

Episode 6: The Evolving Role of Radiation Therapy in Endometrial Cancer - Medscape

Episode 6: The Evolving Role of Radiation Therapy in Endometrial Cancer Medscape

Published: Oct. 24, 2024, 1:44 p.m.

Read Full Article

Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation - BioSpace

Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation BioSpace

Published: Oct. 24, 2024, 5:36 a.m.

Read Full Article

Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation - PR Newswire

Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation PR Newswire

Published: Oct. 24, 2024, 12:08 a.m.

Read Full Article

Latest Articles

Nouscom's Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to 'Intercept' Cancer - The Manila Times

Lisata Therapeutics partners with University of Cincinnati to investigate endometriosis therapy - ICYMI - Proactive Investors USA

MMR Status Doesn’t Impact Outcomes of Chemo in Endometrial Cancer - Cancer Therapy Advisor

Brachytherapy With Modified Rotte-y Applicator for Inoperable Endometrial Cancer: A Case Report - Cureus

Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation - The Week

Hope Medicine touts favourable mid-stage data for endometriosis therapy - FirstWord Pharma

Chemotherapy Combinations and the Phase 3 DUO-E Trial - Cancer Network

Episode 6: The Evolving Role of Radiation Therapy in Endometrial Cancer - Medscape

Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation - BioSpace

Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation - PR Newswire

Subscribe to Our Newsletter